Background: There is poor agreement between observers of equine neurological gait abnormalities using the modified Mayhew grading scale. Objectives: To stimulate a dose-dependent ataxia in horses through xylazine administration and identify quantifiable relevant gait parameters. Study design: Balanced, randomised, 2-way crossover design. Methods: Eight horses were assessed before and after administration of xylazine (low dose and high dose). Gait analyses performed before and after xylazine administration included: 1) kinematic data collected on an equine high-speed treadmill (flat and 10% decline) and from accelerometers placed on head and sacrum; and 2) kinetic data collected on a force plate. Results: All horses developed dose-dependent ataxia. Horses developed a dose-dependent increased stride time, stride length, and time of contact (P<0.0001), and a decreased stride frequency (P<0.0002) after administration of xylazine. Although pelvic acceleration increased in the mediolateral direction (P<0.05) in horses walked on the treadmill, this movement decreased when walking over ground after administration of xylazine (P<0.05). Furthermore, centre of pressure and path length indices changed significantly in horses following administration of xylazine (P<0.05). Main limitations: This study examined one breed of horse (Arabian), all of similar height and weight. Accelerometers were attached to skin, not bone; no correction was made for artefacts from skin displacement. The sedative drug effect is of certain duration, limiting the data collection period. Conclusions: Administration of xylazine induced a dose-dependent ataxia in horses and resulted in significant changes of gait parameters, pelvic accelerations, and stabilographic variables, some of which changed in a dose-dependent fashion. Some of the altered gait parameters in this model were probably a result of overall slowing down of the stride cycle secondary to the sedative effect. Continued efforts to discover and evaluate quantifiable gait parameters that are susceptible to change following development of clinical neurological disease in horses is warranted.
Introduction
In equine neurology, evaluation of gait is necessary for diagnostic and prognostic purposes and for determination of efficacy of therapeutic regimens. Currently, the severity of gait deficits assessed during a neurological examination is graded using a modified ordinal grading scale (modified Mayhew scale) where grade 0 is assigned to horses without neurological deficits and grade 4 is assigned to horses that stumble, trip and fall spontaneously [1, 2] . Grade 5 is reserved for horses that are recumbent. A recent study, however, has shown that there is poor agreement, even between skilled observers of equine gait abnormalities when performing a neurological examination, especially when clinical signs are subtle [3] . Watching the horse in motion is standard practice for both neurological and lameness examinations; however, it has become evident that subjective scoring systems do not suffice for reliable and accurate assessment of horses with gait deficits, in particular when deficits are mild [3] [4] [5] .
Although several studies have evaluated the use of kinematic analyses [6, 7] , kinetic analyses [8] and accelerometers [9] [10] [11] in ataxic horses, there are none that evaluated these techniques simultaneously. Here, we sought to measure gait parameters in horses in which ataxia was induced through administration of xylazine, utilising camera-based motion capture, accelerometers, and a force plate. We hypothesised that xylazine administration will result in dose-dependent development of ataxia and that stride parameters, pelvic accelerations and stabilographic measures will be different before and after a-2 agonist administration. Specifically, we expected to see that the stride cycle will slow down after sedation, resulting in increased stride time and decreased stride frequency. Additionally, after sedation, we expected to demonstrate the development of truncal sway, measurable through increased mediolateral pelvic acceleration and increased range of centre of pressure displacements. Further, we expected to find differences between control and sedated conditions when horses are walked down a slope and while elevating the head.
Materials and methods

Experimental protocol
A balanced, randomised, 2-way crossover design was used, in which 8 horses underwent 2 experiments over 3 weeks with horses being administered xylazine maximally twice per week on 2 nonconsecutive days. Data were collected before (Control LD), and after administration of a low dose of xylazine (xylazine HCl a , 0.2 mg/kg bwt i.v.; LD) and before (Control HD) and after administration of a high dose of xylazine (0.7 mg/kg bwt i.v.; HD). Horses were randomly assigned to either the LD or HD condition for the first day of data collection. LD and HD data were collected 5 min after administration of xylazine.
The first experiment consisted of kinematic data collection from horses walking on a high-speed treadmill (S € ATO I b ) positioned flat or angled at a 10% decline while the head was held in neutral alignment or the head was elevated 20-40°from normal, to reflect what is done during a clinical examination (Fig 1a) . The second experiment consisted of data collection from the horse standing on a force plate (model 9287BA c ; dimensions: 900 9 600 9 100 mm) followed by accelerometer data collection from the horse walking overground (Fig 1b) .
Horses and instrumentation
Eight Arabian horses were used (age: 12 AE 2 years; body mass: 477 AE 10 kg). Ataxia was scored before Control data collection, when horses came off the treadmill directly following LD or HD data collection (T = 12 min; range, 9-15 min), and at T = 5 min during kinetic studies. Ataxia was graded (YSN) according to the modified Mayhew scale and was based on observation of the horse at a walk overground, at a walk with the head elevated, and during tight circles in both directions. Two triaxial USB accelerometers (Model 916-1C d ) were affixed to the horse's body; one on the cranium along the midline of the frontal bone between the eyes (x-axis towards the nose; y-axis towards lateral; z-axis towards dorsal perpendicular to frontal bone), and a second on the midline over the sacrum (x-axis towards the nose; y-axis towards lateral; z-axis towards dorsal). These accelerometer sensors have a AE 16 g single gain mode with 15-bit resolution and user selectable sample rates up to 200 Hz; for this study, data were sampled at 25 Hz. Self-adhesive reflective markers were placed at the following anatomical locations for assessment of leg position during video analysis: right point of shoulder, right olecranon, fetlocks (lateral right side, medial left side), thoracic and pelvic limb right side lateral hoof walls and toe, point of hip, and stifle. Thin rectangular strips were used for the toe markers, while all other markers were circular, 18-22 mm in diameter.
Kinematic data
Kinematic data were collected from horses walking at 1.25 m/s on the treadmill, alternating between level and 10% declined slope with and without head elevation via video and accelerometer measurements. Accelerometer data were also collected from overground walking trials during which horses were walked at their own pace, back and forth over a 40 m flat surface; head position was not altered. A single HotShot e64 camera e set to record at 125 frames/s was used to videotape trials on the treadmill. Prior to treadmill data collection, the recording area was calibrated with a 2 fixed-point reflective marker stick. The same calibration stick was used for all data collection recordings. The placement of the camera and distance from the centre of the treadmill was standardised; the distance from the centre of the camera to the centre of the treadmill was 4.8 m. A calibration recording was taken at the beginning of each data collection using a calibration stick set in the centre of the treadmill. Stride data were determined from these videos. Three trials were collected before and 3 trials were collected after sedation. A trial consisted of 4 situations: flat treadmill with head neutral, flat treadmill with head elevated, declined treadmill with head neutral, and declined treadmill with head elevated. Trials were considered successful if the horse moved through these situations at the speed of the treadmill without requiring encouragement.
Video analysis was conducted using a Dell OptiPlex GX520 (Microsoft Windows 7 Enterprise ). Five sequential strides from each situation in a trial were analysed to determine the times of toe on and toe off and from this the following stride parameters were determined: Stride time (ms): period of time for a complete stride; Stride length (m): distance between 2 successive hoof placements of the same limb; Time of contact (ms; [12] ): duration of the stance phase of the stride; Duty factor [13] : proportion of the stride that a limb is in contact with the ground; Stride frequency: number of stride cycles completed in 1 min. Data across experimental conditions (Control LD, Control HD, LD, HD) and head position were combined to assess whether walking the horse downhill affected stride parameters and data across experimental conditions (Control LD, Control HD, LD, HD) and treadmill angle were combined to assess whether raising the horse's head affected stride parameters.
Accelerometers recorded continuously from the onset of Control data collection until the conclusion of LD or HD data collection from the treadmill and overground walking. The accelerometer that was placed on the head was used for stride identification and for identification of the segments for analysis during which the head was elevated. Stride identification and analysis (Microsoft Excel 2010 f for PC) began with graphing the entire trial period, then distinguishing periods of Control treadmill segments from the standing sedation period and subsequently focusing on each phase of movement. A stride was recognised based on its pattern and a segment containing 5 strides was identified. The lowest points of the first and last peaks for each 5-stride segment were then used as the beginning and end values for calculation of the amplitudes over that 5-stride segment. From these segments the range of accelerations was determined by finding the difference between the absolute values of the minimum and maximum recorded accelerations of each stride. The ranges for Control, LD and HD conditions for each experimental situation were compared to find differences in regularity of stride patterns. Accelerometer data were converted to m/s 2 .
Kinetic data
Horses were positioned with all feet squared up and both front hooves on the force plate. A successful trial consisted of 2 min of data with minimal body or head movements. Force data were captured from the force plate in PowerLab acquisition system using Lab Chart software (Pro v7.2.5) g at a rate of 1000 Hz, and then exported to Microsoft Excel f for further calculations. Two separate blocks of clean data containing no extraneous movements were selected from each horse's recordings, resulting in approximately 30 s of data for analysis per condition. Data were analysed similarly to what has been previously described [14] [15] [16] . Movements of the centre of pressure (COP) are indicative of postural control activity and can be quantified by stabilographic variables derived from motion of the COP. It has been shown that stabilographic data from either the thoracic limbs or pelvic limbs may be useful for detecting and quantifying deficiencies in postural balance [17] . Based on the Fx, Fy and Fz recordings, Moments (Mx, My, Mz) were determined and used to calculate the rostrocaudal and mediolateral movements in centre of pressure (COPx and COPy, respectively) over the trial. COP locations were adjusted for the offset due to the surface of the rubber mat atop the force plate according to manufacturer's specifications. COPx and COPy were used to calculate rostrocaudal and mediolateral displacement as well as total path length. COP displacement was calculated from the range between maximum and minimum values of COPx and COPy. The path length was calculated as the sum of the straight segments connecting the various COP locations during the sample period. This measure represents the amount of all the individual movements of the body that would capture the small twitches and trembling, as opposed to the magnitude of the overall movement that would capture how much the body is swaying. The path length is therefore more dependent on the absolute differences between consecutive COP locations rather than on the maximal individual COP displacement.
Data analysis
Data are reported as median or mean AE s.e. Ataxia was analysed using Kruskal-Wallis. All gait parameters were tested for normality using the Shapiro-Wilk test and analysed using a one-way or 2-way ANOVA with repeated measures and Bonferroni or Tukey's multiple comparison posthoc test to evaluate the effects of sedation (Control LD, Control HD, LD, HD), head position, and treadmill angle where appropriate (IBM SPSS
Results
All horses developed signs of ataxia under both LD and HD conditions. Ataxia was graded as median of 0 out of 5 at Control and increased significantly to a median of 2 out of 5 for the LD condition and a median of 3 out of 5 for the HD condition (P<0.0001), determined at T = 12 min after administration of xylazine.
Stride parameters
As sedative dose increased, stride time (Fig 2a) , stride length (Fig 2b) and time of contact (Fig 2c) significantly increased (P<0.0001) and stride frequency significantly decreased (Fig 2d; P<0.0002 ). There was a significant effect of xylazine dose on duty factor (Fig 2e; P<0 .05) except for when the head was elevated on the decline. In particular, there were significant differences in duty factor between the HD and Control conditions. Across all experimental conditions, all stride parameters were significantly different when horses walked on a flat vs. declined treadmill (P<0.001; Fig 3a) . This difference was present when the head was in its normal position (P<0.02; data not shown separately) and when the head was elevated (P<0.04; data not shown separately). All stride parameters were also significantly different depending on head position (P<0.005; Fig 3b) . Across treadmill angles, head position significantly changed stride parameters under the Control condition (P<0.02; data not shown separately) and under the LD and HD conditions except for duty factor (LD: P<0.003; HD: P<0.002; data not shown separately).
Pelvic acceleration
There was a significant effect of xylazine dose on pelvic acceleration during treadmill walking (Fig 4a) along the rostrocaudal (Ax; P<0.0001), mediolateral (Ay; P<0.05) and dorsoventral (Az; P<0.0001) axes. Rostrocaudal acceleration increased significantly from Control to HD for both head positions (P<0.0001) and from LD to HD for both head positions (P<0.001). Mediolateral acceleration significantly increased from Control to LD (P<0.05) and Control to HD (P<0.0001) for both head positions, and from LD to HD when the head was elevated (P<0.05). Dorsoventral acceleration significantly increased from LD to HD (P<0.0001) and Control to HD (P<0.001) when the head was elevated. Pelvic acceleration during overground walking (Fig 4b) was significantly decreased under the HD condition compared to Control along 2 axes (rostrocaudal: P<0.05; dorsoventral: P<0.05) and significantly decreased between the LD condition compared to Control along the mediolateral axis (P<0.05).
Force plate
Rostrocaudal COP displacement was higher and increased following administration of xylazine. Rostrocaudal COP displacement increased significantly under the HD condition compared to Control (P<0.05). Mediolateral COP displacement was significantly larger under the LD compared to Control condition (P<0.05). The difference between the Control and HD condition did not reach statistical significance (Fig 5a) . The path length was significantly greater under the HD condition when compared to Control (P<0.05; Fig 5b) .
Discussion
Here we show that numerous quantifiable gait parameters are significantly different between sound and xylazine-induced ataxic horses. In addition, this is the first study to show how quantifiable gait parameters change significantly when horses are walked down a slope and when they are walked with their heads in an elevated position. Kinematic data showed a dose-dependent development of longer slower strides in sedated horses, consistent with what 2 other studies have shown [6, 9] . This change is likely to be largely due to the direct central inhibitory effect of xylazine while horses maintain a certain speed on the treadmill, ultimately resulting in the combination of reduced stride frequency and increased stride length. In our study, sedation also induced a dose-dependent longer stance phase, which is different from another study that showed a reduced stance phase in clinically ataxic horses when compared to normal horses [6] . This highlights a difference between xylazine-induced ataxia and clinical ataxia with respect to stride parameters determined from treadmill analyses. Our study demonstrated a significant change in mediolateral pelvic acceleration in horses after sedation. This movement was increased when horses were walked on the treadmill, consistent with our expectation based on the apparent truncal sway seen in these and clinically ataxic horses. However, mediolateral pelvic acceleration was decreased in horses that were walked overground. The increased mediolateral acceleration when horses were walked on the treadmill may have been due to the fact that horses had to maintain a certain speed, in contrast to when the horses were walked overground. In the latter condition, the inhibitory sedative effect probably reduced accelerations in all directions. These results are similar to what was shown by L opez-Sanrom an et al. [9] . We also found significant effects of sedation on COP displacement and path length measures, consistent with increased motion and postural sway present in xylazine-induced ataxic horses. These measurements are in alignment with observations of clinically ataxic horses and this study shows that we can objectively quantify these movement patterns, thus reducing observer bias. This is a unique study in which 3 different gait assessment techniques were used simultaneously. The force plate provided 2 measures of stability that both showed significant differences between sedated and sound horses. These stabilographic measures might be very informative to collect on ataxic horses since maintaining balance at a standstill is likely to be compromised in affected horses. However, limitations are that the equipment is expensive, typically requiring installation in a dedicated area, and that about 2 min of data, collected from an animal that is immobile, are needed for analysis. These requirements are difficult to realise under clinical conditions. Although stride parameters were significantly affected by level of sedation it is unclear to which extent these changes were attributable to the inhibitory effect of the sedation vs. the ataxia. Treadmill analysis is the most expensive technique used in this study and would be hard to replicate under clinical conditions; however, this technique proved in particular important to show how changes in slope and head position affect the horse's gait and this technique provided a visual assessment of the horse's gait. Accelerometers are cheap and easy to instrument the horse with. We showed significant differences between the groups of horses both when walked on the treadmill and when walked overground using this technique. We believe that further study of gait parameters using accelerometers, in particular improvement of methods to detect truncal sway, could be of interest for objectifying the assessment of neurological horses. The limitation is that the instruments do not provide other parameters such as distance or rotational angle. Inertial measurement units, however, incorporate accelerometers, gyroscopes and magnetometers, and might provide the user with informative variables related to ataxia such as stabilographic indices during stance and motion as well as inter-and intralimb irregularities during the stride cycle.
There is currently no alternative (reversible) equine model in which to study ataxia. A side effect of a-2 agonists is induction of ataxia [6, [9] [10] [11] ; 2 significant advantages of a xylazine-induced equine ataxia model are that the resulting ataxia is dose-dependent, as seen here and as has been reported previously [18] , and the mechanism of development of the gait deficits is the same across animals. Here, all HD horses were graded 3 and LD horses were grade 1 or 2 for ataxia. The high dose (~330 mg xylazine per horse) induced obvious gait deficits yet did not result in falling down or nearly falling down, putting the horse in grade category 3. The low dose (~94 mg xylazine per animal) induced noticeable, but mild and variable gait deficits placing the animals in grades 1 and 2. This relative predictability of ataxia severity and, therefore, the potential to study a group of similarly affected animals is more difficult to realise when clinically neurological horses are used. The main disadvantage of this model is the inhibition of locomotor activity [19] that contributes to development of gait deficits. The only study available that compared clinically ataxic horses to detomidine-induced ataxic horses [6] showed that some movement patterns were different between these groups of horses; however, that study only evaluated treadmill-based video analyses of gait. We propose that this model is useful for determining quantifiable gait parameters to help distinguish normal from abnormal horses despite some gait parameters being affected by sedation independently. Two clinical challenges to elicit gait abnormalities in mildly affected horses during the neurological examination are to walk the horse down a slope and to walk the horse with its head held in an elevated position. Both of these challenges indeed resulted in significantly shorter faster strides with a reduced stance phase when evaluated on the treadmill in both control and sedated animals. This is consistent with what we see clinically as most horses suspend their foot in the air subjectively longer before making contact with the ground under these conditions. The origin of these gait changes is thought to stem from altered general proprioceptive input both from the body itself and through changed visual input. The current study demonstrates that these gait alterations are quantifiable and that they indeed change during these challenges.
How these parameters change in horses when walked overground remains to be investigated.
The inherent problem veterinary neurologists face is that, with 5 discrete grades, our current scale lacks discrimination. In other species, different testing paradigms have been developed for recovery of locomotor function. In experimental spinal cord injury research, relatively complex scales based on assessment of animals in open field conditions are used to identify subtle differences between animals [20, 21] that are typically paired with other, more objective, measures that are designed to test a similar or related function, such as walking over a walkway [22] or treadmill [23] . In canine neurology the ordinal modified Tarlov scale that scores gait from 0 to 5 [24] is being expanded upon by, amongst others, the use of treadmill based gait analyses [25] . Other types of gait analyses may need to be included in our assessment of neurological disease in horses, such as is done in other species [21, 25, 26] . For example, utilising the fact that ataxia is a result of irregularities in limb movements, measures of regularity of stepping sequences or stride parameters should be included in future studies. Moreover, well-designed behavioural outcome measures may also identify anatomical tracts involved in specific locomotor activity and/or potential mechanisms of injury and recovery.
The main limitations in this study include the use of one type of horse, which may limit comparison of these data to data collected from other horses. Further, accelerometers were attached to skin, not bone, which may have resulted in artefacts due to skin displacement, which was not accounted for in the analysis. Although the effect of xylazine is of short duration (~20 min), limiting the data collection period, this did not appear to affect our study since all data were easily collected within this time frame.
Results from this study demonstrate and corroborate with other studies that there are measurable gait parameters that are different between ataxic and sound horses. All 3 techniques used here provided relevant data for studying ataxia; important findings were the development of rostrocaudal and mediolateral changes in COP displacement and changes in pelvic acceleration after administration of xylazine. Furthermore, we demonstrated that changing the horse's head position and walking the horse down a slope alters stride parameters and pelvic accelerations. Continued efforts to discover quantifiable gait parameters in horses that are susceptible to change following development of neurological disease is warranted to keep the field of clinical and experimental equine neurology moving forward. 
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